$46.58
6.20% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
NL0011606264
Symbol
MRUS
Sector
Industry

Merus N.V. Stock price

$46.58
-4.77 9.29% 1M
+1.37 3.03% 6M
+19.08 69.38% YTD
+22.61 94.33% 1Y
+16.92 57.05% 3Y
+30.87 196.50% 5Y
+36.54 363.94% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-3.08 6.20%
ISIN
NL0011606264
Symbol
MRUS
Sector
Industry

Key metrics

Market capitalization $3.19b
Enterprise Value $2.57b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 71.47
P/S ratio (TTM) P/S ratio 88.76
P/B ratio (TTM) P/B ratio 4.53
Revenue growth (TTM) Revenue growth -21.33%
Revenue (TTM) Revenue $35.93m
EBIT (operating result TTM) EBIT $-230.96m
Free Cash Flow (TTM) Free Cash Flow $-156.90m
Cash position $632.27m
EPS (TTM) EPS $-3.91
P/E forward negative
P/S forward 34.62
EV/Sales forward 28.29
Short interest 12.72%
Show more

Is Merus N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Merus N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Merus N.V. forecast:

16x Buy
100%

Analyst Opinions

16 Analysts have issued a Merus N.V. forecast:

Buy
100%

Financial data from Merus N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
36 36
21% 21%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 70 70
28% 28%
196%
- Research and Development Expense 192 192
29% 29%
533%
-228 -228
42% 42%
-636%
- Depreciation and Amortization 2.50 2.50
12% 12%
7%
EBIT (Operating Income) EBIT -231 -231
42% 42%
-643%
Net Profit -245 -245
38% 38%
-681%

In millions USD.

Don't miss a Thing! We will send you all news about Merus N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Merus N.V. Stock News

Neutral
GlobeNewsWire
9 days ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:
Positive
Seeking Alpha
10 days ago
Merus is nearing a major milestone with zenocutuzumab's potential FDA approval for NRG1+ NSCLC/PDAC, with a PDUFA date of February 4, 2025. Petosemtamab, targeting 1st and 2nd-line HNSCC, shows promise with updated data to be presented at ESMO Asia Congress in December 2024. Financially stable with $782.9 million in cash, Merus has strategic partnerships with Gilead, Eli Lilly, Incyte, and Ono ...
Neutral
GlobeNewsWire
11 days ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the United States Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) go...
More Merus N.V. News

Company Profile

Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

Head office Netherlands
CEO Bill Lundberg
Employees 229
Founded 2003
Website www.merus.nl

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today